GASTROESOPHAGEAL REFLUX News, Sports, Shopping, Travel information

Reflux
Looking for Reflux? Search over 15,000 sites with one clicks. Your source for everything under the sun!
www.findstuff.com

Digestive System gastroesophageal Reflux Disease - Pr Inside
2008-12-05 19:49:01 - digestive system gastroesophageal reflux disease - a new market research report on http://www.companiesandmarkets.com www.companiesandmarkets.com/summary-market-report/digestive-syst .. life science analytics´, "digestive ...
www.pr-inside.com

Xenoport's Acid Reflux Drug Fails Endpoint
xenoport, a biopharmaceutical company, has announced top-line results from a phase ii clinical trial that examined the ability of xp19986 extended-release tablets to reduce symptoms experienced by subjects with gastroesophageal reflux disease.
www.pharmaceutical-business-review.com

Xenoport Reports Results From A Phase 2 Clinical Trial Of Xp19986 As A Treatment For The Symptoms Of Gastroesophageal ...
xenoport, inc. (nasdaq:xnpt) announced today top-line results from a phase 2 clinical trial that examined the ability of xp19986 ( arbaclofen placarbil ) extended-release tablets to reduce symptoms experienced by subjects with gastroesophageal reflux disease, or gerd. the primary analysis comparing xp19986 to placebo did not reach statistical significance. however, pre-defined subgroup analyses ...
www.centredaily.com

Xenoport Reports Results From A Phase 2 Clinical Trial Of Xp19986 As A ... - Msn Moneycentral
xenoport, inc. xnpt announced today top-line results from a phase 2 clinical trial that examined the ability of xp19986 ( arbaclofen placarbil ) extended-release tablets to reduce symptoms experienced by subjects with gastroesophageal reflux disease ...
news.moneycentral.msn.com

Xenoport's Acid Reflux Drug Fails Endpoint - Pharmaceutical Business Review
according to the company, the primary analysis comparing xp19986 to placebo did not reach statistical significance. however, pre-defined subgroup analyses showed statistically significant benefits of xp19986 on a number of important parameters ...
www.pharmaceutical-business-review.com

Xenoport Reports Results From A Phase 2 Clinical Trial Of Xp19986 As A Treatment For The Symptoms Of Gastroesophageal ...
santa clara, calif.----xenoport, inc. announced today top-line results from a phase 2 clinical trial that examined the ability of xp19986 extended-release tablets to reduce symptoms experienced by subjects with gastroesophageal reflux disease, or gerd.
biz.yahoo.com

Addex Starts Phase Iib Adx10059, Proton Pump Inhibitor Combination Study In Gerd Patients
addex pharmaceuticals, the allosteric modulation company, started recently a phase iib trial of adx10059 as an add-on therapy to proton pump inhibitors (ppis) for the treatment of gastroesophageal reflux disease (gerd), the cause of heartburn and other symptoms.
www.bioresearchonline.com

Update 1-xenoport's Acid Reflux Drug Fails Mid-stage Study - Reuters
dec 2 (reuters) - biopharmaceutical company xenoport inc (xnpt.o: quote , profile , research , stock buzz ) said its treatment to reduce symptoms of acid reflux failed to meet the main goal in a mid-stage study, sending its shares down 34 percent ...
www.reuters.com

Xenoport Trial For Reflux Disease Treatment Fails - Forbes
biotech company xenoport inc. said tuesday results from a midstage trial comparing the tablet xp19986 with a placebo for the treatment of a reflux disease did not reach statistical significance. shares of the stock sank on the news, losing $7.76, or ...
www.forbes.com

Xenoport Trial For Reflux Disease Treatment Fails
biotech company xenoport inc. said tuesday results from a midstage trial comparing the tablet xp19986 with a placebo for the treatment of a reflux disease did not reach statistical significance.
biz.yahoo.com

Symptoms Of gastroesophageal Reflux Disease (gerd)/heartburn
gerd symptoms can occur at any time. however, they usually occur after overeating, or lying down after a big meal. symptoms may last for a few minutes or a few hours.
www.thirdage.com

Addex Starts Phase Iib Adx10059, Proton Pump Inhibitor Combination ... - Phramalive.com
geneva, switzerland, 2 december 2008 - addex pharmaceuticals (swx:adxn), the allosteric modulation company, started today a phase iib trial of adx10059 as an add-on therapy to proton pump inhibitors (ppis) for the treatment of gastroesophageal reflux ...
www.pharmalive.com

New Techniques Help In Fight Against Esophageal Cancer - International Herald Tribune
half a century ago, my grandmother died of esophageal cancer. for decades preceding her death, a bottle of milk of magnesia was her steady companion because she suffered daily from heartburn, now known as gastroesophageal reflux disease, or gerd. but ...
www.iht.com

(afx Uk Focus) 2008-12-02 14:38 Update 1-xenoport's Acid Reflux Drug Fails Mid-stage Study
(adds details, share movement) dec 2 (reuters) - biopharmaceutical company xenoport inc said its treatment to reduce symptoms of acid reflux failed to meet the main goal in a mid-stage study, sending its shares down 34 percent before the bell. the drug xp19986 did not prove to be statistically significant compared to a dummy drug in reducing heartburn episodes, a symptom of acid reflux disease. ...
www.iii.co.uk

Finding, And Treating, Esophageal Cancer
half a century ago, my grandmother died of esophageal cancer. for decades preceding her death, a bottle of milk of magnesia was her steady companion because she suffered daily from heartburn, now known as gastroesophageal reflux disease, or gerd. but many years passed before a link was clearly established between chronic irritation of the esophagus by stomach acid and this usually fatal cancer. ...
www.ajc.com

Finding, And Treating, Esophageal Cancer - Atlanta Journal Constitution
half a century ago, my grandmother died of esophageal cancer. for decades preceding her death, a bottle of milk of magnesia was her steady companion because she suffered daily from heartburn, now known as gastroesophageal reflux disease, or gerd. but ...
www.ajc.com

Xenoport Shares Dive On Disappointing Study - Forbes
shares of xenoport inc. plunged tuesday after the biotechnology company said its heartburn drug candidate failed to improve severe heartburn symptoms in a midstage study. the stock plummeted $10.01, or 34.6 percent, to close at $18.91. shares plunged ...
www.forbes.com

Journal Chest: December Highlighted Studies
( american college of chest physicians ) new studies in the december issue of the journal chest show that copd may be linked to both osteoporosis and acid reflux, while asthma may be linked to poor mental health.
www.eurekalert.org

Addex Starts Phase Iib Adx10059, Proton Pump Inhibitor Combination Study In Gerd Patients
addex pharmaceuticals, the allosteric modulation company, started today a phase iib trial of adx10059 as an add-on therapy to proton pump inhibitors for the treatment of gastroesophageal reflux disease, the cause of heartburn and other symptoms.
biz.yahoo.com

Dynamic Outlines Initial Target Markets For Pharmaceutical Cannabinoid ... - Biloxi Sun Herald
palm springs, calif., dec. 5 /prnewswire-firstcall/ -- dynamic alert limited (otc bulletin board: dymc) is pleased to announce that it has now identified its target markets for its pharmaceutical product line-up. the modalities will include a lozenge ...
www.sunherald.com